中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Dendritic Cell-Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease

文献类型：期刊论文

作者Yi, Wenzhe3,5,6; Sun, Fang2; Qian, Xindi5,6; Xu, Xiaoxuan3,5,6; Yan, Dan5,6; Zhao, Zhiwen3,5,6; Xu, Leiming2; Wang, Dangge4; Li, Yaping1,3,5,6
刊名ADVANCED MATERIALS
出版日期2025-06-22
页码16
关键词dendritic cells fas/fas legend interaction inflammatory bowel disease liposomes
ISSN号0935-9648
DOI10.1002/adma.202420113
英文摘要Inflammation is a key driver of intestinal inflammatory diseases, such as inflammatory bowel disease (IBD). While biologics have demonstrated notable success in treating some patients, there remains a critical need for alternative therapeutic strategies to address primary and secondary non-responders. In this study, a dendritic cell (DC)-based biohybrid immunomodulator is developed to alleviate intestinal inflammation, demonstrating remarkable efficacy in combating IBD. This biohybrid immunomodulator is engineered by conjugating resolvin E1-loaded liposomes with Fas ligand (FasL)-transfected DCs. Elevated Fas expression is observed in intestinal tissue samples from IBD patients, and the immunomodulator effectively reduced inflammation by selectively eliminating Fas+CD8+ T cells and neutrophils. The therapeutic potential of this approach is validated in both mouse and rabbit models of IBD, where it exhibites significant anti-inflammatory effects. Furthermore, the immunomodulator can be manufactured using human peripheral blood mononuclear cells and bone marrow-derived DCs, demonstrating a robust capacity to induce T cell apoptosis. This study presents a feasible and customizable strategy for mitigating intestinal inflammation, offering a promising advancement in the treatment of IBD.
WOS关键词ACTIVATION ; CANCER
资助项目National Natural Science Foundation of China ; Shanghai Advanced Research Institute, Chinese Academy of Sciences, China ; Strategic Priority Research Program of the Chinese Academy of Grant[XDC0290302] ; National Key R&D Program of China[2022YFC3401404] ; Science and Technology Commission of Shanghai Municipality[24J22800600] ; Shandong Laboratory Program[SYS202205] ; [32170935]
WOS研究方向Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics
语种英语
WOS记录号WOS:001512803600001
出版者WILEY-V C H VERLAG GMBH
源URL[http://119.78.100.183/handle/2S10ELR8/318633]  
专题新药研究国家重点实验室
通讯作者Wang, Dangge; Li, Yaping
作者单位1.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264000, Peoples R China
2.Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Gastroenterol, Shanghai 200092, Peoples R China
3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
4.Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Precis Res Ctr Refractory Dis, Sch Med, Shanghai 201620, Peoples R China
5.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China
6.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Yi, Wenzhe,Sun, Fang,Qian, Xindi,et al. Dendritic Cell-Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease[J]. ADVANCED MATERIALS,2025:16.
APA Yi, Wenzhe.,Sun, Fang.,Qian, Xindi.,Xu, Xiaoxuan.,Yan, Dan.,...&Li, Yaping.(2025).Dendritic Cell-Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease.ADVANCED MATERIALS,16.
MLA Yi, Wenzhe,et al."Dendritic Cell-Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease".ADVANCED MATERIALS (2025):16.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。